Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abingdon Health PLC ( (GB:ABDX) ) has provided an update.
Abingdon Health plc, a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med‑tech, operates as a contract development and manufacturing organisation for lateral flow assays, taking projects from concept through to routine manufacturing. The Group also offers regulatory consultancy and analytical testing to help in vitro diagnostic and medical device clients secure approvals in major markets.
The company has granted 3,096,000 share options under its existing EMI scheme to all UK-based employees with at least 12 months’ service, representing 1.23% of its issued share capital. Half of these options will be allocated in April 2026 and the remainder in April 2027, with all options exercisable at nil cost three years after allocation, aligning staff incentives more closely with the company’s long‑term performance.
Spark’s Take on ABDX Stock
According to Spark, TipRanks’ AI Analyst, ABDX is a Neutral.
Abingdon Health PLC’s overall stock score is primarily influenced by its mixed financial performance, with strong revenue growth overshadowed by profitability and cash flow challenges. The technical analysis indicates a neutral trend, lacking strong momentum. The valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively result in a moderate overall score.
To see Spark’s full report on ABDX stock, click here.
More about Abingdon Health PLC
Abingdon Health plc is a UK-based med-tech contract service provider specialising in the development, manufacturing and regulatory support of rapid diagnostic tests and medical technologies. The Group’s CDMO operations focus on lateral flow assays across infectious disease, clinical testing, companion diagnostics, animal health and environmental testing for an international customer base.
Through its regulatory services units, Compliance Solutions (Life Sciences) and IVDeology, Abingdon supports in vitro diagnostic and wider medical device companies with quality systems, technical files and market access in the US, EU and UK. Its Abingdon Analytical subsidiary provides analytical testing and performance evaluation from its Doncaster facilities to generate data required for regulatory approvals.
Average Trading Volume: 197,430
Technical Sentiment Signal: Buy
Current Market Cap: £21.34M
For an in-depth examination of ABDX stock, go to TipRanks’ Overview page.